Skip to main content

Genome-Based Therapeutics Targeted Drug Discovery and Development: Workshop Summary (2012) / Chapter Skim
Currently Skimming:

Appendix A: Workshop Agenda
Pages 59-64

The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.


From page 59...
... · To investigate the economic drivers, incentives, and models for genomic-based strategies for drug development.
Read the entire page →
From page 60...
... 8:45­9:00 A.M.Current Use of Genetic and Genomic Strategies in Drug Development Nicholas Davies Partner, Pharmaceutical and Life Sciences Practice, PwC 9:00­9:15 A.M.Economic Incentives for Genetic and Genomic Strategies Mark Trusheim Visiting Scientist and Executive-in-Residence, MIT Sloan School of Management; President, Co-Bio Consulting 9:15­9:30 A.M.Perceived Challenges in Genomic-Based Drug Development Garret A FitzGerald Professor of Medicine and Pharmacology and McNeil Professor in Translational Medicine and Therapeutics; Associate Dean for Translational Research; Chair, Department of Pharmacology; Director, Institute for Translational Medicine and Therapeutics, University of Pennsylvania School of Medicine
Read the entire page →
From page 61...
... Ho Director, Translational Oncology, Pfizer Inc. 10:50­11:10 A.M.Use of Genetics to Inform Drug Development of a Novel Treatment for Schizophrenia Laura Nisenbaum Senior Research Advisor, Pharmacogenomics, Translational Medicine and Tailored Therapeutics, Eli Lilly and Company 11:10­11:30 A.M.A Genetic Approach to the Treatment of Cystic Fibrosis Peter Mueller Executive Vice President, Global Research and Development; Chief Scientific Officer, Vertex Pharmaceuticals Incorporated 11:30 A.M.­ Discussion with Speakers and Attendees 12:15 P.M.
Read the entire page →
From page 62...
... Foundations and Drug Development Walter Capone Chief Operating Officer, Multiple Myeloma Research Foundation
Read the entire page →
From page 63...
... BREAK 3:00­3:15 P.M. Repurposing of Drugs Christopher Austin Director of the Division of Pre-Clinical Innovation; Scientific Director, NIH Center for Translational Therapeutics; National Center for Advancing Translational Sciences, National Institutes of Health 3:15­3:30 P.M.Pharmacy Benefit Management and Pharmacogenomics Felix W
Read the entire page →
From page 64...
... CONCLUDING REMARKS Geoffrey Ginsburg Director, Center for Genomic Medicine, Duke University 5:45 P.M.
Read the entire page →

Key Terms

  • translational sciences
  • geoffrey ginsburg
  • translational medicine
  • advancing translational
  • chief scientific

  • development session
  • scientific officer
  • pfizer inc
  • drug discovery
  • inform drug

  • translational oncology
  • genetic alliance
  • translational therapeutics
  • multiple myeloma
  • economic incentives

  • executive vice
  • paradigms session
  • michelle penny
  • evolving paradigms
  • landscape session

  • sharon terry
  • sloan school
  • tailored therapeutics
  • concluding remarks
  • medco research

  • mcneil professor
  • participants geoffrey
  • current landscape
  • remarks geoffrey
  • takeda oncology


    • This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
    More information on Chapter Skim is available.